News | February 18, 2008

Triple Drug Therapy Reduces MACE in AFib Treated with PCI

February 19, 2008 - A regimen of aspirin, clopidogrel and coumadin started at discharge decreased mortality and major adverse cardiac events (MACE) while keeping bleeding to acceptable levels in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) with stent placement, reports a study in the February 26, 2008 issue of the Journal of the American College of Cardiology.

The researchers in the study, led by Gregory Y.H. Lip, MD, of City Hospital (Birmingham, UK), advise not to use drug-eluting stents (DES) in patients with AF requiring anticoagulation because of the increased bleeding risk that would accompany the addition of prolonged dual antiplatelet therapy.

The study included 426 elderly patients (mean age 71.5 years) with AF undergoing PCI with stenting at 2 hospitals in Spain between 2001 and 2006. Half of the patients were discharged with triple therapy (coumadin, aspirin, and clopidogrel). After 2 years of follow-up, patients who were not on coumadin at discharge had significantly higher rates of mortality, MACE, and other adverse events as compared with patients who were on a regimen including coumadin when they left the hospital.

In the study, patients given DES (n=174, 40.1% of cohort) had a higher rate of stent thrombosis (2.8% vs. 0%, P=0.034). This fact, combined with the necessity for prolonged dual antiplatelet therapy compared with bare-metal stents (BMS), convinced the study authors to recommend against the use of DES in anti-coagulated AF patients.

The study authors noted that deciding on the proper anticoagulant/antiplatelet regimen in AF patients undergoing PCI amounts to a balancing act in each individual, in which the risk of bleeding (increased in triple therapy) must be weighed against the risk of stroke, stent thrombosis, and other ischemic events (increased with AF and stent implantation).

The study concluded: “in those patients with AF treated with PCI/stents who have a low risk of bleeding complications, a triple-therapy regimen should be the elective antithrombotic drug treatment approach.”

In an editorial accompanying the study, Steven Francescone, M.D., and Jonathan L. Halperin, M.D., both of the Mount Sinai Medical Center (New York, NY), agreed that “for those at low risk of serious bleeding, treatment with triple therapy may be the best option.”

In addition, they wrote that, “BMS may be preferable to DES in patients with AF who have risk factors for thromboembolism requiring chronic anticoagulation to reduce the need for prolonged combination therapy.”

For more information: www.acc.org

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init